Xtl Biopharmaceuticals (XTLB) Change in Cash (2009 - 2016)
Xtl Biopharmaceuticals (XTLB) posted quarterly Change in Cash of -$507000.0 for Q2 2016, down 116.73% year-on-year from $3.0 million in Q3 2015, and up 4.7% on a QoQ basis from -$532000.0 in Q4 2015.
Xtl Biopharmaceuticals (XTLB) Change in Cash (2009 - 2016) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Change in Cash for 8 consecutive years, with -$507000.0 the latest figure, recorded in Q2 2016.
- Quarterly Change in Cash fell 116.73% year-over-year to -$507000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $1.5 million (down 43.88% YoY) and the FY2025 annual result came in at -$295000.0, up 70.94% from the prior year.
- Change in Cash rose to -$507000.0 in Q2 2016 per XTLB's latest filing, from -$532000.0 in the prior quarter.
- Over the last five years, Change in Cash for XTLB reached as high as $4.5 million in Q1 2012 and fell as low as -$1.9 million in Q2 2012.
- A 5-year average of $221937.5 and a median of -$282000.0 in 2014 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2014 — Change in Cash plunged 585.71% — and 2015, when it soared 4951.67%.
- Year by year, Change in Cash stood at -$1.1 million in 2012, then decreased by 22.56% to -$1.3 million in 2013, then jumped by 87.78% to -$158000.0 in 2014, then slumped by 236.71% to -$532000.0 in 2015, then gained by 4.7% to -$507000.0 in 2016.
- According to Business Quant data, Change in Cash over the past three periods registered -$507000.0, -$532000.0, and -$501000.0 for Q2 2016, Q4 2015, and Q3 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -22.03 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 243.78 Mn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 417.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -153.10 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Xtl Biopharmaceuticals | 2.50 Bn | 2.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | -507,000.00 |
| Dec 31, 2015 | -532,000.00 |
| Sep 30, 2015 | -501,000.00 |
| Jun 30, 2015 | 3.03 Mn |
| Dec 31, 2014 | -158,000.00 |
| Sep 30, 2014 | -276,000.00 |
| Jun 30, 2014 | 60,000.00 |
| Mar 31, 2014 | -288,000.00 |
| Dec 31, 2013 | -1.29 Mn |
| Sep 30, 2013 | 3.15 Mn |
| Jun 30, 2013 | -662,000.00 |
| Mar 31, 2013 | -42,000.00 |
| Dec 31, 2012 | -1.06 Mn |
| Sep 30, 2012 | 84,000.00 |
| Jun 30, 2012 | -1.93 Mn |
| Mar 31, 2012 | 4.47 Mn |
| Dec 31, 2011 | -755,000.00 |
| Sep 30, 2011 | -103,000.00 |
| Jun 30, 2011 | -326,000.00 |
| Mar 31, 2011 | -495,000.00 |